Pulmatrix (PULM) Research & Development (2013 - 2026)
Pulmatrix (PULM) posted Research & Development of $3000.0 for Q1 2026, up 200.0% sequentially from -$3000.0 in Q4 2025, and down 84.21% YoY from $19000.0 in Q1 2025.
Pulmatrix (PULM) Research & Development (2013 - 2026) Analysis & Trends
Pulmatrix has reported Research & Development for 14 years, with the latest figure at $3000.0 in Q1 2026.
- Quarterly Research & Development fell 84.21% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22000.0 (down 99.4% YoY) and the FY2025 annual result came in at $38000.0, down 99.47% from the prior year.
- Research & Development grew to $3000.0 in Q1 2026 per PULM's latest filing, from -$3000.0 in the prior quarter.
- Over five years, Research & Development peaked at $5.3 million in Q3 2022 and troughed at -$3000.0 in Q4 2025.
- A 5-year average of $2.4 million and a median of $3.5 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 50.96% in 2022, then plunged 150.0% in 2025.
- Over 5 years, Research & Development stood at $4.5 million in 2022, then decreased by 21.29% to $3.5 million in 2023, then plunged by 99.83% to $6000.0 in 2024, then slumped by 150.0% to -$3000.0 in 2025, then surged by 200.0% to $3000.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3000.0, -$3000.0, and $8000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 814,000.00 |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Sep 30, 2023 | 3.96 Mn |
| Jun 30, 2023 | 4.17 Mn |
| Mar 31, 2023 | 3.87 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 5.29 Mn |
| Jun 30, 2022 | 4.34 Mn |
| Mar 31, 2022 | 4.15 Mn |
| Dec 31, 2021 | 2.96 Mn |
| Sep 30, 2021 | 4.03 Mn |